EPISODE · Jun 11, 2026 · 3 MIN
今天3分钟我们来聊聊17个疗程NK细胞治疗，晚期肝癌患者多个肿瘤缩小，生存期超4年
from 源于细胞BioInsid的个人播客
肝癌5年生存率仅12.1%，晚期患者难寻有效疗法。一案例显示，17个疗程NK细胞治疗后，患者NK细胞比例增近7倍，免疫功能修复，胸水腹水减少，肿瘤缩小，生存期超4年。研究表明足疗程治疗是关键，为晚期患者带来新希望。 参考文献： Oncotargets and Therapy，晚期肝癌NK细胞治疗17个疗程病例报告 International Immunopharmacology，2017，免疫细胞治疗周期与生存期关联研究（≥4周期 mOS 50个月 vs ＜4周期 24个月） 前往小宇宙评论区与主播互动
Embed this episode
Ready to play
今天3分钟我们来聊聊17个疗程NK细胞治疗，晚期肝癌患者多个肿瘤缩小，生存期超4年
0:00
3:25
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
Frequently Asked Questions
How long is this episode of 源于细胞BioInsid的个人播客?
This episode is 3 minutes long.
When was this 源于细胞BioInsid的个人播客 episode published?
This episode was published on June 11, 2026.
Can I download this 源于细胞BioInsid的个人播客 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!